Targeting Fibrosis in Kidney, Bone Marrow, and Urological Diseases

Event Details

Meeting Summary

Download the Meeting Minutes (PDF, 145.54 KB) .

Meeting Focus

Discuss Means of Detecting and Measuring Pathologic Fibrosis in Humans

Questions to be answered

1. Can we differentiate between pathologic fibrosis and that of normal aging?
2. Does fibrosis correlate with organ dysfunction?
3. Does imaging of fibrosis correlate with organ dysfunction, recovery, and regression?
4. What novel biomarkers or technologies should be pursued to detect and measure pathologic fibrosis?

Steering Committee

NIDDK Members

Tamara Bavendam, Terry Bishop, Ed Doo, Deborah Hoshizaki, Chris Ketchum,
Ziya Kirkali, Maren Laughlin, Tracy Rankin, and Krystyna Rys-Sikora

NIBIB Member

Christina Liu

Agenda

January 7, 2014

7:30 a.m.

Registration

8:30 a.m.

Opening Remarks and Objectives
Dr. Griffin Rodgers

State-of-the-Art Lectures

(20 min. each followed by 10 min. discussion)
Moderator: Dr. Deborah Hoshizaki

8:45 a.m.

Mechanisms of Fibrosis
Dr. Thomas Wynn

JAK2 Story in Myelofibrosis
Dr. Kenneth Kaushansky

Advances in Liver Fibrosis Research
Dr. Scott Friedman

10:15 a.m.

Break

Detection (Imaging) of Pathologic Fibrosis

(20 min. + 10 min. for questions)
Moderator: Dr. Maren Laughlin

10:45 a.m.

Molecular Imaging
Dr. Bryan Fuchs

New Tools for Measuring and Understanding Pathologic Fibrosis
Dr. Ben Humphreys

Fibrosis and Prostate Disease
Dr. William Ricke

12:15 p.m.

Lunch (on your own)
A box lunch may be ordered the morning of the workshop with this form (PDF, 40.52 KB) .

Pathologic Fibrosis and Organ Dysfunction

(20 min. + 10 min. for questions)
Moderator: Dr. Terry Bishop

1:15 p.m.

Urinary Obstruction and Fibrosis
Dr. Jill Macoska

Biology of Fibrosis and Mechanisms for Reversal Therapy
Dr. Raghu Kalluri

Hematologic Fibrosis: Monitoring Dysfunction and Recovery
Dr. Joachim Deeg

2:45 p.m.

Break

FDA Procedures for Qualification

(20 min. each + 10 min. for questions)
Moderator: Dr. Michael Flessner

3:15 p.m.

Perspectives on Biomarker Test Validation From OIR/CDRH at FDA
Dr. Kellie Kelm

Biomarker Qualification at CDER, FDA
Dr. Shashi Amur

Device Qualification
Dr. Brian Garra

4:45 p.m.

Summary
Dr. Robert Star and Dr. Michael Flessner

5:00 p.m.

Adjournment